Elevated alkaline phosphatase velocity strongly predicts overall survival and the risk of bone metastases in castrate-resistant prostate cancer

Urologic Oncology: Seminars and Original Investigations

Volumn 32, Issue 6, 2014, Pages 761-768

  Metwalli, Adam R ^a   Rosner, Inger L ^a   Cullen, Jennifer ^a   Chen, Yongmei ^a   Brand, Timothy ^a   Brassell, Stephen A ^a   Lesperance, James ^a   Porter, Christopher ^a   Sterbis, Joseph ^a   McLeod, David G ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Alkaline phosphatase; Alkaline phosphatase velocity (APV); Bone metastasis; Bone metastasis free survival; Overall survival; Prostate cancer; Prostate specific antigen (PSA); PSA doubling time (PSADT)

Indexed keywords

ALKALINE PHOSPHATASE; TESTOSTERONE; ANTIANDROGEN; PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; CANCER MORTALITY; CANCER RISK; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; COHORT ANALYSIS; CONTROLLED STUDY; ENZYME KINETICS; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; BONE NEOPLASMS; KAPLAN MEIER METHOD; KINETICS; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PREDICTIVE VALUE; PROCEDURES; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RISK FACTOR; SECONDARY; STATISTICS AND NUMERICAL DATA; TIME;

AGED; ALKALINE PHOSPHATASE; ANDROGEN ANTAGONISTS; BONE NEOPLASMS; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; KINETICS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT (HEALTH CARE); PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS;

EID: 84905251273     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2014.03.024     Document Type: Article

References (21)

1. Sonpavde G., Pond G.R., Berry W.R., et al. Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy. Urol Oncol 2010, 30:607-613.
2. Cook R.J., Coleman R., Brown J., et al. Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer. Clin Cancer Res 2006, 12:3361-3367.
3. Jung K., Miller K., Wirth M., Albrecht M., Lein M. Bone turnover markers as predictors of mortality risk in prostate cancer patients with bone metastases following treatment with zoledronic acid. Eur Urol 2011, 59:604-612.
4. Lein M., Wirth M., Miller K., et al. Serial markers of bone turnover in men with metastatic prostate cancer treated with zoledronic acid for detection of bone metastases progression. Eur Urol 2007, 52:1381-1387.
5. Smith M.R., Saad F., Coleman R., et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet 2012, 379:39-46.
6. Smith M.R., Saad F., Oudard S., et al. Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. J Clin Oncol 2013, 31:3800-3806.
7. Smith M.R., Kabbinavar F., Saad F., et al. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol 2005, 23:2918-2925.
8. Harris E.K., Brown S.S. Temporal changes in the concentrations of serum constituents in healthy men. Distributions of within-person variances and their relevance to the interpretation of differences between successive measurements. Ann Clin Biochem 1979, 16:169-176.
9. Van Steirteghem A.C., Robertson E.A., Young D.S. Variance components of serum constituents in healthy individuals. Clin Chem 1978, 24:212-222.
10. Brassell S.A., Dobi A., Petrovics G., Srivastava S., McLeod D. The Center for Prostate Disease Research (CPDR): a multidisciplinary approach to translational research. Urol Oncol 2009, 27:562-569.
11. Hussain M., Tangen C.M., Higano C., et al. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol 2006, 24:3984-3990.
12. Pound C.R., Partin A.W., Eisenberger M.A., Chan D.W., Pearson J.D., Walsh P.C. Natural history of progression after PSA elevation following radical prostatectomy. J Am Med Assoc 1999, 281:1591-1597.
13. Freedland S.J., Humphreys E.B., Mangold L.A., et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. J Am Med Assoc 2005, 294:433-439.
14. Wilt T.J., Brawer M.K., Jones K.M., et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012, 367:203-213.
15. Ozu C., Nakashima J., Horiguchi Y., Oya M., Ohigashi T., Murai M. Prediction of bone metastases by combination of tartrate-resistant acid phosphatase, alkaline phosphatase and prostate specific antigen in patients with prostate cancer. Int J Urol 2008, 15:419-422.
16. Brown J.E., Cook R.J., Major P., et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 2005, 97:59-69.
17. Robinson D., Sandblom G., Johansson R., et al. Prediction of survival of metastatic prostate cancer based on early serial measurements of prostate specific antigen and alkaline phosphatase. J Urol 2008, 179:117-122. [discussion 22-3].
18. Garnero P., Buchs N., Zekri J., Rizzoli R., Coleman R.E., Delmas P.D. Markers of bone turnover for the management of patients with bone metastases from prostate cancer. Br J Cancer 2000, 82:858-864.
19. Jung K., Lein M., Stephan C., et al. Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications. Int J Cancer 2004, 111:783-791.
20. Smith M.R., Cook R., Lee K.A., Nelson J.B. Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer. Cancer 2011, 117:2077-2085.
21. Mason M.D., Sydes M.R., Glaholm J., et al. Oral sodium clodronate for nonmetastatic prostate cancer-results of a randomized double-blind placebo-controlled trial: Medical Research Council PR04 (ISRCTN61384873). J Natl Cancer Inst 2007, 99:765-776.